Revance's strategy focuses on capturing market share from incumbents like Allergan's Botox by offering a differentiated product profile in a market projected to reach $8 billion. As a Crown subsidiary, the business concentrates on core aesthetic and therapeutic product lines including DAXXIFY and the RHA Collection of dermal fillers. The company operates internationally through partnerships with Teoxane SA in Switzerland and Shanghai Fosun Pharmaceutical in China for product commercialization.
Cyborg Score Rationale
DAXXIFY's rapid market adoption with one million vials distributed demonstrates strong product-market fit and commercial traction. The company generated $256.95 million in revenue over the last twelve months despite operating losses, showing significant revenue scale. The acquisition by Crown provides financial stability and integration within a larger skincare platform.
Top Insights
DAXXIFY is the fastest-growing neurotoxin in the U.S., with one million vials distributed by September 2025
Acquired by Crown Laboratories in February 2025 at $3.65 per share, transitioning from NASDAQ-traded to private subsidiary
DAXXIFY is approved for glabellar lines and cervical dystonia; pipeline includes phase II trials for forehead lines, lateral canthal lines, upper limb spasticity, and plantar fasciitis
Operating with approximately 597 employees as a focused, science-driven biotechnology organization
Named Competitors
BOTOX — Leading botulinum toxin for cosmetic and therapeutic indications
Xeomin — Botulinum toxin alternative for aesthetic and therapeutic use
Dysport — Botulinum toxin for aesthetic and therapeutic applications
Recent Developments
(February 2025) Acquisition by Crown Laboratories completed at $3.65 per share
(September 2025) DAXXIFY achieved one million vials distributed milestone
(Late 2024) Generated $256.95 million in trailing twelve-month revenue
Open the full interactive Revance Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.